| Chemical Properties | Back Directory | [density ]
1.350±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
2.482±0.40(predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
ABBV-467 is a selective MCL-1 inhibitor (Ki: <0.01 nM). ABBV-467 induces apoptosis. ABBV-467 induces cancer cell death and inhibits tumor growth in models of hematological malignancies, such as multiple myeloma[1]. | [in vivo]
ABBV-467 (12.5 mg/kg, i.v., once per week for 3 weeks) exhibits significant antitumor activity in t(4;14)-translocated multiple myeloma mouse models[1]. | Animal Model: | t(4;14) (chromosomal translocation between chromosome 4 and chromosome 14)-translocated high-risk multiple myeloma NOD-SCID mice[1] | | Dosage: | 6.25 mg/kg and 12.5 mg/kg | | Administration: | Intravenous injection (i.v.), once per week for 3 weeks | | Result: | Resulted in a maximal tumor delay of 82% at 6.25 mg/kg and complete tumor regression at 12.5 mg/kg. |
| [References]
[1] Yuda J, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med (Lond). 2023 Oct 25;3(1):154. DOI:10.1038/s43856-023-00380-z |
|
|